DE69329247T2 - Kristallisierung von m-csf - Google Patents

Kristallisierung von m-csf

Info

Publication number
DE69329247T2
DE69329247T2 DE69329247T DE69329247T DE69329247T2 DE 69329247 T2 DE69329247 T2 DE 69329247T2 DE 69329247 T DE69329247 T DE 69329247T DE 69329247 T DE69329247 T DE 69329247T DE 69329247 T2 DE69329247 T2 DE 69329247T2
Authority
DE
Germany
Prior art keywords
csf
csfα
dimer
polypeptide
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329247T
Other languages
German (de)
English (en)
Other versions
DE69329247D1 (de
Inventor
Andrew Bohm
Lisa Fear
Robert Halenbeck
Jarmila Jancarik
Sung-Hou Kim
Kirston Koths
Jayvardhan Pandit
Eric Taylor
Ralph Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of California
Original Assignee
University of California
Chiron Corp
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Chiron Corp, University of California Berkeley filed Critical University of California
Publication of DE69329247D1 publication Critical patent/DE69329247D1/de
Application granted granted Critical
Publication of DE69329247T2 publication Critical patent/DE69329247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69329247T 1992-06-09 1993-06-09 Kristallisierung von m-csf Expired - Lifetime DE69329247T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Publications (2)

Publication Number Publication Date
DE69329247D1 DE69329247D1 (de) 2000-09-21
DE69329247T2 true DE69329247T2 (de) 2001-05-31

Family

ID=25406334

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329247T Expired - Lifetime DE69329247T2 (de) 1992-06-09 1993-06-09 Kristallisierung von m-csf

Country Status (7)

Country Link
US (2) US5866114A (OSRAM)
EP (2) EP0668914B1 (OSRAM)
JP (2) JPH08507916A (OSRAM)
AT (1) ATE195553T1 (OSRAM)
CA (1) CA2137793C (OSRAM)
DE (1) DE69329247T2 (OSRAM)
WO (1) WO1993025687A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
DK1772464T3 (da) 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
EP1706137A2 (en) * 2004-01-21 2006-10-04 Chiron Corporation M-csf muteins and uses thereof
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
HUE044179T2 (hu) 2009-12-10 2019-10-28 Hoffmann La Roche Elsõsorban humán CSF1R extracelluláris domén 4-et megkötõ antitestek és ezek alkalmazása
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
BR112016029460A2 (pt) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc métodos para tratar artrite reumatoide
EA036261B1 (ru) 2014-10-29 2020-10-20 Файв Прайм Терапьютикс, Инк. Комбинированное лечение злокачественного новообразования
EP3237447B1 (en) 2014-12-22 2020-12-02 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
DE68918331T2 (de) * 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP0506866B1 (en) * 1989-12-21 1993-10-20 Novo Nordisk A/S Method for crystallization of enzymes
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden

Also Published As

Publication number Publication date
EP0668914A1 (en) 1995-08-30
WO1993025687A1 (en) 1993-12-23
DE69329247D1 (de) 2000-09-21
US6184354B1 (en) 2001-02-06
JP2004285076A (ja) 2004-10-14
EP0955365A2 (en) 1999-11-10
US5866114A (en) 1999-02-02
EP0955365A3 (en) 2000-12-20
ATE195553T1 (de) 2000-09-15
JPH08507916A (ja) 1996-08-27
EP0668914B1 (en) 2000-08-16
CA2137793A1 (en) 1993-12-23
CA2137793C (en) 2003-04-22

Similar Documents

Publication Publication Date Title
DE69329247T2 (de) Kristallisierung von m-csf
DE69936105T2 (de) Menschliche tslp nukleinsäuren und polypeptide
DE68916537T3 (de) Herstellung eines insulinähnlichen, wachstümsfaktor bindenden proteins.
DE69024291T2 (de) Rezeptoren für Tumornekrosisfaktor-alpha und -beta
US5326558A (en) Megakaryocytopoietic factor
Hymowitz et al. IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding
DE69014162T2 (de) Morphogenetisches Knochenprotein.
DE69017753T3 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
DE68928043T2 (de) Interleukin-4-Rezeptoren
DE68929387T2 (de) Interleukin-1-Inhibitoren
DE3789859T2 (de) Formen des Koloniestimulierungsfaktors 1.
DE3856238T2 (de) DNA, die für Proteine kodiert, die menschliches IL-1 binden
Schreuder et al. Refined crystal structure of the interleukin‐1 receptor antagonist: presence of a disulfide link and a cis‐proline
DE69016508T2 (de) Interleukin-7-Rezeptoren.
DE69229862T2 (de) Cysteinfreie il-6 mutanten
DE69326255T2 (de) Elam-1 bindende peptide und zusammensetzungen
DE69636052T2 (de) Mpl-liganden analoga
US6025146A (en) Identification of M-CSF agonists and antagonists
DE69020161T2 (de) Rezeptoren für granulozytenkolonien stimulierenden faktor.
DE60320304T2 (de) Kristallstruktur von menschlichem il-18
AU640686B2 (en) A megakaryocytopoietic factor
DE60032598T2 (de) Il-1 eta dna und polypeptide
DE69932259T2 (de) Il-1zeta, il-1zeta spleissvarianten, und xrec2 dnas und polypeptide
DE69433745T2 (de) Modifizierte, verkürzte regulatoren des komplementsystems
DE69932247T2 (de) Menschliches il-1 epsilon dna und polypeptide

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, O, US